PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
NCT06792162
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
Carilizumab and Apatinib
Sponsor
Peking University Third Hospital